Drugs.com - New Drug Approvals
New drug approvals news from Drugs.com. Comprehensive, up-to-date drug news for consumers and healthcare professionals.
-
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
PLYMOUTH MEETING, Pa., Oct. 30, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases... -
Ilumya (tildrakizumab-asmn) Approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis
MUMBAI, India and PRINCETON, N.J., Oct. 30, 2026 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies)... -
FDA Approves Lucamzi (ranibizumab-blrz), a Biosimilar to Lucentis
Solna, Sweden 27 October 2026 – Lucamzi™ (ranibizumab-blrz) biosimilar to Lucentis® has been approved by FDA in the US. Xbrane will finalize preparation for an upcoming launch of the product during 2027 together with its... -
Pfizer’s Talzenna Plus Xtandi FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
NEW YORK--(BUSINESS WIRE) October 26, 2026 -- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) to the treatment of... -
Novo’s Awiqli Receives FDA Approval as the First and Only Once-Weekly Insulin for Children 10 Years of Age and Older with Type 2 Diabetes
PLAINSBORO, N.J., Oct. 23, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection 700 units/mL, the first once-weekly, long-acting basal insulin, as an... -
FDA Approves Subcutaneous Induction Regimen for AbbVie's Skyrizi (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
NORTH CHICAGO, Ill., Oct. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for Skyrizi (risankizumab-rzaa) for adults with moderately to severely... -
BioCryst Announces U.S. FDA Approval of Orladeyo 150 mg Oral Pellets for Adults and Adolescents with HAE
RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for use of the oral... -
Ultomiris Received Accelerated Approval in the US as First and Only C5 Complement Inhibitor to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy
21 October 2026 -- Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. Based on...